Chatham Rock Phosphate

Chatham Rock Phosphate closed a non-brokered private placement. It raised C$158,150 from 3,162,995 units at 5 cents each.

Chatham agreed to sell Avenir Makatea to Austure Industries. The deal is worth $1.4-million (Australian).

Chatham Rock Phosphate granted stock options to its directors. The grant covers 8.75 million shares at 5.4 cents for 10 years.

Chatham Rock Phosphate gave an update on its NewCo term sheet. Due diligence is complete and it now targets a binding agreement in 2025.

Chatham Rock Phosphate reported results of its 2025 annual meeting. Shareholders ratified all matters at the Nov. 13, 2025 AGM.

Chatham Rock Phosphate signed a framework deal to sell Avenir Makatea. Austure will pay $1.4-million (Australian) including a 20% stake.

Chatham Rock Phosphate progressed its RailPhos rail feasibility study. As at Oct. 22, it had contacted all landholders and met Queensland Rail.

Chatham Rock Phosphate launches a non-brokered private placement. It will raise up to $500,000 (Canadian) by Dec. 5, 2025.

Chatham Rock Phosphate is negotiating financing for Chatham Rise. A partner could earn up to 75% ownership by funding development.

Chatham Rock Phosphate to supply Korella phosphate to Cloncurry plant. The plant will make DCP/MCP, replacing 50,000 tonnes of yearly imports.